Abcodia's (bio)bankroll

Abcodia Ltd. is hoping therapeutics companies will be able to pinpoint the very start of disease by using the biotech's massive, longitudinal biobank to find out exactly when levels of a marker or target in a seemingly healthy individual begin to deviate from the person's historical baseline.

The biobank contains samples from more than 200,000 postmenopausal women and includes a decade of annual samples from a subset of 50,000 women. The samples were collected in the U.K. Collaborative Trial for Ovarian Cancer Screening (UKCTOCS) by the University College London...